These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15505625)

  • 1. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
    Waters JS; Moss C; Pyle L; James M; Hackett S; A'hern R; Gore M; Eisen T
    Br J Cancer; 2004 Nov; 91(10):1763-8. PubMed ID: 15505625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
    Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
    J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
    Stadler WM; Halabi S; Rini B; Ernstoff MS; Davila E; Picus J; Barrier R; Small EJ;
    Cancer; 2006 Sep; 107(6):1273-9. PubMed ID: 16909426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
    Van Veldhuizen PJ; Hussey M; Lara PN; Mack PC; Gandour-Edwards R; Clark JI; Lange MK; Crawford DE
    Am J Clin Oncol; 2009 Oct; 32(5):453-9. PubMed ID: 19487915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
    Rini BI; Weinberg V; Small EJ
    Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
    Amato RJ; Khan M
    Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
    Padrik P; Leppik K; Arak A
    Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
    Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
    Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
    Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
    Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
    Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
    Rini BI; Vogelzang NJ; Dumas MC; Wade JL; Taber DA; Stadler WM
    J Clin Oncol; 2000 Jun; 18(12):2419-26. PubMed ID: 10856102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
    Chung EK; Posadas EM; Kasza K; Karrison T; Manchen E; Hahn OM; Stadler WM
    Am J Clin Oncol; 2011 Apr; 34(2):150-4. PubMed ID: 20395787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
    Jonasch E; Lal LS; Atkinson BJ; Byfield SD; Miller LA; Pagliaro LC; Feng C; Tannir NM
    BJU Int; 2011 Mar; 107(5):741-747. PubMed ID: 21355978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic chemotherapy for metastatic renal cell carcinoma.
    Stadler WM
    Urologe A; 2004 Sep; 43 Suppl 3():S145-6. PubMed ID: 15164180
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
    Neri B; Doni L; Gemelli MT; Fulignati C; Turrini M; Di Cello V; Dominici A; Maleci M; Mottola A; Ponchietti R; Raugei A; Valsuani G; Cini G
    J Urol; 2002 Sep; 168(3):956-8. PubMed ID: 12187198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
    Marur S; Eliason J; Heilbrun LK; Dickow B; Smith DW; Baranowski K; Alhasan S; Vaishampayan U
    Urology; 2008 Oct; 72(4):898-902. PubMed ID: 18692873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.